Osteonecrosis of the mandible associated with bevacizumab therapy

Bevacizumab is a humanized antibody that blocks vascular endothelial growth factor and is of great value for the treatment of advanced cancer. Several adverse effects following its administration have been reported. To date, only 8 cases of osteonecrosis of the jaws associated with bevacizumab (with...

Full description

Saved in:
Bibliographic Details
Published in:Oral surgery, oral medicine, oral pathology and oral radiology oral medicine, oral pathology and oral radiology, 2013-06, Vol.115 (6), p.e32-e36
Main Authors: Santos-Silva, Alan Roger, DDS, PhD, Belizário Rosa, Giuliano Augusto, DDS, Castro Júnior, Gilberto de, MD, PhD, Dias, Reinaldo Brito, DDS, PhD, Prado Ribeiro, Ana Carolina, DDS, PhD, Brandão, Thaís Bianca, DDS, MSc
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - adverse effects
Bevacizumab
Dentistry
Humans
Jaw Diseases - chemically induced
Jaw Diseases - pathology
Male
Mandible - pathology
Middle Aged
Osteonecrosis - chemically induced
Osteonecrosis - pathology
Surgery
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bevacizumab is a humanized antibody that blocks vascular endothelial growth factor and is of great value for the treatment of advanced cancer. Several adverse effects following its administration have been reported. To date, only 8 cases of osteonecrosis of the jaws associated with bevacizumab (without any association with bisphosphonates) have been reported. The aim of this article was to describe an original case of bevacizumab-related osteonecrosis of the jaw. A 61-year-old man diagnosed with advanced renal cell carcinoma was undergoing treatment with intravenous bevacizumab and temsirolimus when he spontaneously developed mandible osteonecrosis, which resolved after 3 months of conservative management. The present case reinforces recent speculation that the anti-angiogenic properties of bevacizumab may represent a potential new source of osteonecrosis of the jaws in patients undergoing cancer treatment. Multidisciplinary teams in cancer care should be aware of the possible association between osteonecrosis of the jaw and bevacizumab therapy.
ISSN:2212-4403
2212-4411
DOI:10.1016/j.oooo.2013.02.001